Table 1 Patient, clinical, tumor, and treatment characteristics
Number of patients (n) | 39 |
|---|---|
Age; mean ± sd | 70.7 ± 6.7 |
Smoking status; n (%) | 29 (74.4%) |
Alcohol consumption; n (%) | |
Yes, regular | 1 (2.6%) |
Periodically | 23 (59.0%) |
No | 15 (38.5%) |
Medical comorbidities; n (%) | |
Diabetes mellitus | 7 (17.9%) |
Hypertension | 28 (71.8%) |
Operations/abdominal | 17 (43.6%) |
Other malignancies | 36 (92.3%) |
PSA before diagnosis; median (min – max) ng/mL | 10.0 (3.9–38.8) |
PSA before radiotherapy; median (min–max) ng/mL | 0.6 (0.1–14.3) |
T stage; n (%) | |
T2 | 27 (69.2%) |
T3 | 12 (30.8%) |
Gleason score; n (%) | |
6 | 7 (17.9%) |
7 | 30 (76.9%) |
8 | 1 (2.6%) |
9 | 1 (2.6%) |
N stage; n (%) | |
N0 | 38 (97.4%) |
N1 | 1 (2.6%) |
Type of radiotherapy; n (%) | |
Definitive | 26 (66.7%) |
Postoperative | 13 (33.3%) |
Dose volume groups; n (%) | |
Prostate | 5 (12.8%) |
Prostate and seminal vesicles | 13 (33.3%) |
Prostate, seminal vesicles, and lymph nodes | 21 (53.8%) |
Risk groups | |
Low risk | 5 (12.8%) |
Intermediate risk | 26 (66.7%) |
High risk | 8 (20.5%) |